
zzso and its wholly owned European subsidiary zzso AB are developing an zzso zzso gene therapy as a treatment for cancer in the US and Europe, zzso Phase III trials in patients with head and neck cancer are zzso and a number of clinical trials in other cancer indications have been zzso zzso 201 is being reviewed by the zzso for approval in zzso syndrome zzso under the provisions of exceptional zzso the therapy is available on a compassionate use basis to eligible zzso cancer patients under a protocol zzso by the US zzso The zzso zzso zzso gene is deleted or zzso in many zzso cells and is one of the most frequently zzso genes in human zzso The zzso protein is one of the most intricate elements in the zzso zzso zzso and a zzso in the gene zzso it is believed to result in a decreased ability of a cell to zzso Thus replacing this gene via zzso zzso gene therapy is hoped to result in increased zzso where it is zzso 201 is available for licensing, although zzso zzso retaining partial or full rights to the therapy in the zzso zzso entered into a license agreement with The University of Texas System and MD Anderson Cancer Center in zzso The technologies zzso include zzso and zzso zzso zzso The collaboration has yielded exclusive patent and licensing rights to numerous zzso zzso entered into a collaboration with zzso zzso zzso (now zzso to develop zzso based on zzso zzso in October zzso However, in June 2001 this relationship was restructured and zzso assumed responsibility for the worldwide development of all zzso products including zzso zzso and acquired all marketing and zzso rights with respect to those zzso zzso initiated two phase III trials in head and neck cancer (in June 2000 and May 2001) at about 80 sites in the zzso Canada and zzso the first is a comparative study of zzso 201 and IV zzso in 240 patients with zzso head and neck zzso The second is for the combination of zzso 201 and standard chemotherapy, compared with standard chemotherapy alone, in 288 patients with zzso zzso cell zzso of the head and zzso zzso expects to complete regulatory filings for advanced zzso head and neck cancer in the US and zzso within zzso zzso phase II data of zzso 201 in a zzso of patients with zzso zzso head and neck cancer zzso prompted zzso to seek accelerated approval for zzso 201 in December zzso The company has filed a request with the zzso to accept a zzso zzso zzso zzso the first regulatory step in the accelerated approval zzso zzso requested immediate initiation of the zzso Approval rolling zzso with completion of the filing process expected before the end of zzso zzso had presented combined results from three zzso zzso and Europe) phase II studies of zzso 201 in 217 patients with zzso zzso cell zzso of the head and neck confirming previous safety and efficacy results of the zzso In April 2004, the Southwest Oncology Group initiated a similar clinical trial using zzso 201 for the treatment of stage III or IV zzso cell zzso of the oral zzso or zzso that is able to be removed zzso The study assessed the zzso efficacy and safety of administering zzso 201 at the time of surgery for suppression of remaining zzso cells, followed by a combination of chemotherapy and radiation zzso The previous trial was a phase II study that afforded zzso access to surgical specialists in cancer and zzso the company's ongoing pivotal phase III studies in advanced zzso zzso Sixty patients with head and neck cancer will undergo surgery at ten US sites and receive zzso 201 zzso (and not zzso as used in the former zzso followed by a combination of zzso and zzso In September 2003, zzso 201 was granted designation as a Fast Track Drug zzso development zzso by the zzso for zzso survival and delaying time to disease progression in patients with zzso zzso zzso cell zzso of the head and zzso Previously, in February 2003, zzso 201 received orphan drug designation from the zzso for head and neck zzso Phase I trials in the US for the treatment of zzso lung cancer have been zzso zzso (formerly zzso zzso zzso initiated phase II trials in the zzso Europe and Canada for zzso lung zzso zzso injection of zzso 201 in patients with zzso zzso was safe and resulted in expression of the zzso zzso zzso administration of zzso 201 to the lower airways of patients with zzso cell lung zzso resulted in symptomatic improvement and improved lung function in some zzso In November 2003, according to a Clinical Trials zzso between the Division of Cancer Treatment and Diagnosis zzso of the National Cancer Institute zzso and zzso a zzso phase zzso study with zzso gene therapy administered in the form of an oral zzso or zzso for patients with oral zzso has been zzso This is the first trial to investigate the effect of this treatment on oral zzso that are at high risk for developing into full blown zzso In September 2006, the zzso granted orphan drug status to zzso 201 for the treatment of zzso following zzso application for the zzso The company intends to provide the therapy on a compassionate use basis to qualifying patients in zzso 201 has been successfully used in the treatment of a zzso patient on a compassionate use basis under a protocol zzso by the zzso Based on these interim findings, zzso has decided to continue making the therapy available through a compassionate use zzso to eligible zzso patients who have relapsed after standard treatment as part of zzso protocols at qualifying institutions in the zzso worldwide, exclusive license to a family of US patents covering a combination therapy comprised of zzso 201 in combination with several zzso of zzso growth factor receptors zzso such as zzso mark zzso mark and zzso mark was granted to zzso by The University of Texas MD Anderson Cancer Center in November zzso In February 2006, zzso exclusively zzso a broad patent zzso Patent zzso 6 zzso zzso originally issued to to the Board of Regents of The University of Texas zzso the patent covers any therapeutic zzso therapy when applied in combination with conventional cancer therapy such as radiation or zzso zzso zzso was awarded a patent from the US Patent and zzso Office in June 2005 that directly covers many of the special features of its zzso 201 molecular zzso US Patent zzso zzso is one of a family of patents that cover zzso 201 that have been issued to the Board of Regents of The University of Texas System and exclusively licensed to zzso To date, zzso controls 30 issued patents relevant to the product covering compositions, therapeutic methods of administering the product in virtually any form, alone and in conjunction with the most widely used zzso and radiation treatments, as well as its production, and has a large number of pending patent applications in the US and in foreign countries relating to its zzso zzso In December 2004, the US Patent and zzso Office issued Patent zzso zzso entitled zzso zzso zzso zzso and zzso zzso the patent is the broadest zzso zzso patent to date, covering any zzso carrying the zzso gene under the control of any zzso Previously, Patent zzso zzso covering methods for the administration of zzso 201 to cancer patients including virtually all of those routes currently being used for zzso delivery was zzso In addition, US Patent zzso zzso which broadly covers zzso zzso with the zzso zzso zzso in pharmaceutical compositions, was zzso This patent extends zzso patent coverage for its zzso zzso gene therapy product to the year zzso not taking into account possible patent zzso In February 2003, the US Patent and zzso Office issued patent zzso zzso entitled zzso zzso zzso zzso and zzso covering any zzso DNA zzso that encodes the zzso gene positioned under the control of a zzso patents issued in 2002 include Patent zzso zzso broadly covering all zzso zzso compositions (including zzso that express adequate zzso in amounts sufficient to suppress the growth of or kill cancer cells in zzso The patent also covers zzso zzso which incorporates a specific type of promoter that helps cells to express the zzso zzso zzso zzso zzso has a number of US patents that relate to the clinical use of zzso zzso gene therapy in cancer as zzso or in combination with one or more zzso drugs, radiation therapies or other agents that have a damaging effect on the DNA or survival of zzso zzso Patent zzso zzso cancer zzso patent with broad claims directed to combination therapy with the zzso gene and conventional chemotherapy or radiation was issued in China in August zzso Patent zzso zzso entitled zzso zzso DNA zzso Agents and zzso was issued to the Board of Regents of The University of Texas System and was exclusively zzso to zzso zzso zzso 

